Technical Analysis for RNXT - RenovoRx, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.29 | 6.60% | 0.08 |
RNXT closed up 6.6 percent on Friday, November 22, 2024, on 5.77 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Above Upper BB | Strength | 0.00% |
| Alert | Time |
|---|---|
| 5x Volume Pace | about 13 hours ago |
| Up 2 ATRs | about 13 hours ago |
| Up 10% | about 13 hours ago |
| 200 DMA Support | about 15 hours ago |
| Rose Above Previous Day's High | about 15 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/15/2024
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Evofosfamide Gemcitabine Gastrointestinal Cancer Locally Advanced Pancreatic Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Evofosfamide Gemcitabine Gastrointestinal Cancer Locally Advanced Pancreatic Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.35 |
| 52 Week Low | 0.5488 |
| Average Volume | 45,600 |
| 200-Day Moving Average | 1.21 |
| 50-Day Moving Average | 1.04 |
| 20-Day Moving Average | 1.09 |
| 10-Day Moving Average | 1.14 |
| Average True Range | 0.12 |
| RSI (14) | 73.47 |
| ADX | 19.72 |
| +DI | 34.36 |
| -DI | 11.61 |
| Chandelier Exit (Long, 3 ATRs) | 1.23 |
| Chandelier Exit (Short, 3 ATRs) | 1.12 |
| Upper Bollinger Bands | 1.24 |
| Lower Bollinger Band | 0.93 |
| Percent B (%b) | 1.16 |
| BandWidth | 28.17 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.03 |
| MACD Histogram | 0.0198 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.88 | ||||
| Resistance 3 (R3) | 1.91 | 1.75 | 1.78 | ||
| Resistance 2 (R2) | 1.75 | 1.60 | 1.73 | 1.75 | |
| Resistance 1 (R1) | 1.52 | 1.50 | 1.44 | 1.49 | 1.72 |
| Pivot Point | 1.35 | 1.35 | 1.31 | 1.34 | 1.35 |
| Support 1 (S1) | 1.12 | 1.20 | 1.04 | 1.09 | 0.86 |
| Support 2 (S2) | 0.96 | 1.11 | 0.94 | 0.83 | |
| Support 3 (S3) | 0.73 | 0.96 | 0.80 | ||
| Support 4 (S4) | 0.70 |
